

Short CV - Vasiliki Koliaraki

Independent position(s) as a principal investigator

2022 - present	Researcher B' (Associate Prof. rank) BSRC “Alexander Fleming”, Athens, Greece <i>Research Areas: Mesenchymal cell biology, Intestinal inflammation and cancer</i>
2016 - 2022:	Researcher C' (Assistant Prof. rank) BSRC “Alexander Fleming”, Athens, Greece <i>Research Areas: Mesenchymal cell biology, Intestinal inflammation and cancer</i>

Education trajectory

1998 –2003:	B.Sc. in Biology School of Science, Department of Biology, National and Kapodistrian University of Athens, Greece <i>Dissertation: Study of the acidic ribosomal proteins P0, P1, P2 of the silkworm Bombyx Mori and their genes</i>
2004 –2009:	Ph.D. in Biochemistry Hellenic Pasteur Institute, Athens, Greece, and Department of Medicine, School of Health Sciences, National and Kapodistrian University of Athens, Greece <i>Thesis: Study of hepcidin</i>
2009 - 2015:	Post-Doctoral Research Associate BSRC “Alexander Fleming”, Athens, Greece Dr. George Kollias Lab

Tutoring and Training

2019 - 2023	Lecture: “Signalling pathways and drug development” MSc in “Drug Development”, Department of Medicine, National & Kapodistrian University of Athens
2016 – 2023:	- Series of Lectures in Inflammation and Cancer. - Journal Club Module co-organization. MSc in “Molecular Biomedicine: Disease mechanisms, biological therapies and bioinnovation” Medical School, National & Kapodistrian University of Athens and BSRC Alexander Fleming
2017:	“Cellular and molecular mechanisms in the microenvironment of cancer” MSc in “Molecular and Applied Physiology” Medical School, National & Kapodistrian University of Athens.
2013 - present:	Supervision of 3 postdoctoral fellows, 5 Ph.D. students, and 4 MSc students

Funding

2022 - 2025	ELIDEK – 2nd HFRI Call for the support of Faculty Members and Researchers <i>Title: Delineating the contribution of fibroblast heterogeneity and functions in mucosal repair, re-epithelization, and regeneration of the intestine</i>
2022 - 2025	Worldwide Cancer Research <i>Title: Notch3 as a regulator of cancer-associated fibroblast reprogramming and functions in intestinal cancer</i>
2023 - 2024	Global Grants for Gut Health <i>Title: Aetiopathogenic microbiota-induced stromal changes in the aging intestine</i>
2018 - 2021	ELIDEK – 1st HFRI Call for the support of PostDoc Researchers (PI: M. Sarris)

2017 - 2019	<p><i>Title:</i> The role of mesenchymal-derived IGF1 in intestinal homeostasis and the promotion of colitis and colitis-associated cancer</p> <p>Fondation Sante Biomedical Grant</p> <p><i>Title:</i> Identification and functional characterization of mesenchymal cell lineages in intestinal development and carcinogenesis</p>
2017 - 2018	<p>European Crohn's and Colitis Organisation (ECCO)</p> <p><i>Title:</i> The role of mesenchymal cells in IBD pathogenesis: focus on mechanisms underlying villous blunting/atrophy</p>
2016 - 2019	<p>Starting grant from the "Stavros Niarchos Foundation"</p> <p><i>Title:</i> The origin, identities and function of intestinal mesenchymal cells during embryonic development and in intestinal inflammation and cancer</p>

Organization of Conferences

2019	EMBO Workshop on "Mesenchymal Cells in Inflammation, Immunity and Cancer", Athens, 19-23 May 2019 – Co-organizer
2022	Aegean Conference on "Mesenchymal cells in health and disease", Chania, Greece, 3 – 8 June September 2022 – Co-organizer (<i>upcoming</i>)

Bibliography

Metrics: 28 publications, h-index:19, 1545 citations (Source: [Google Scholar](#))

List of publications (last 10 years):

1. **Koliaraki V***, Dotto GP, Buckley CD, Kollias G. (2022) Mesenchymal cells in health and disease, *Nat Immunol*, 23(10):1395-1398.
2. Chalkidi N, Paraskeva C, **Koliaraki V**. (2022) Fibroblasts in intestinal homeostasis, damage, and repair, *Front Immunol*, 13:924866.
3. Melissari MT, Henriques A, Tzaferis C, Prados A, Sarris ME, Chalkidi N, Mavroeidi D, Chouvardas P, Grammenoudi S, Kollias G, **Koliaraki V**. Col6a1+/CD201+ mesenchymal cells regulate intestinal morphogenesis and homeostasis. *Cell Mol Life Sci*. 2021; 79(1):1.
4. **Koliaraki V***, Prados A, Armaka M, Kollias G. The mesenchymal context in inflammation, immunity and cancer. *Nat Immunol*. 2020; 21(9):974-982.
5. Melissari MT, Chalkidi N, Sarris ME, **Koliaraki V**. Fibroblast reprogramming in gastrointestinal cancer. *Front. Cell Dev. Biol*. 2020; 8: 630-639.
6. **Koliaraki V***, Henriques A, Prados A, Kollias G. Unfolding innate mechanisms in the cancer stroma: the emerging role of mesenchyma. *J Exp Med*. 2020; 217(4):e20190457.
7. Roulis M, Kaklamanos A, Schernthanner M, Bielecki P, Zhao J, Kaffe E, Frommelt LS, Qu R, Knapp MS, Qu R, Henriques A, **Koliaraki V**, Jiao J, Brewer R, Zhao X, Breyer RM, Soriano P, Aidinis V, Jain D, Su B, Herschman HR, Kluger Y, Kollias G and Flavell RA. Paracrine orchestration of intestinal tumorigenesis by a confined mesenchymal niche. *Nature*. 2020; 580(7804):524-529.
8. Hatzioannou A, Banos A, Sakelaropoulos T, Fedonidis C, Vidali MS, Koehne M, Boon L, Henriques A, **Koliaraki V**, Georgiadis P, Beyer M, Chavakis T, Boumpas D, Tsirigos Aristotelis, Verginis P. A cell intrinsic role of IL33 in the establishment of Treg cell function in the tumor microenvironment. *Nat Immunol*. 2020;21(1):75-85.
9. Patsalos A, Tzerpos P, Halasz L, Nagy G, Pap A, Giannakis N, Lyroni K, **Koliaraki V**, Pintye E, Dezso B, Kollias G, Spilianakis CG, Nagy L. The BACH1-HMOX1 regulatory axis is indispensable for proper macrophage subtype specification and skeletal muscle regeneration. *J Immunol*. 2019; JI1900553.
10. **Koliaraki V***, Chalkidi N, Henriques A, Tzaferis C, Polykratis A, Waisman A, Muller W, Hackam DJ, Pasparakis M, Kollias G. Innate sensing through mesenchymal TLR4/ MyD88 signals promote spontaneous intestinal tumorigenesis. *Cell Rep*. 2019;26(3):536-546.e4. (*co-correspondence)
11. Henriques A, **Koliaraki V***, Kollias G. Mesenchymal MAPKAPK2/HSP27 drives intestinal carcinogenesis. *Proc Natl Acad Sci USA*. 2018; 115(24): E5546-E5555. (*co-correspondence)

12. Nagashima K, Sawa S, Nitta T, Prados A, **Koliaraki V**, Kollias G, Nakashima T, Takayanagi H. Targeted deletion of RANKL in M cell inducer cells by the Col6a1-Cre driver. *Biochem Biophys Res Commun*. 2017. 493(1):437-443.
13. **Koliaraki V**, Pallangyo CK, Greten FR, Kollias G. Mesenchymal cells in colon cancer. *Gastroenterology* 2017;152(5):964-979.
14. Prados A, Kollias G, **Koliaraki V**. CollagenVI-Cre mice: A new tool to target stromal cells in secondary lymphoid organs. *Sci Rep*. 2016; 8(6): 33027.
15. **Koliaraki V***, and Kollias G. Isolation of intestinal mesenchymal cells from adult mice. *Bio-protocol*. 2016; 6(18): e1940. (*corresponding author)
16. **Koliaraki V***, Pasparakis M, Kollias G*. IKKbeta in intestinal mesenchymal cells promotes initiation of colitis-associated cancer. *J Exp Med*. 2015;212(13):2235-51. (*co-correspondence)
17. Roulis M, Nikolaou C, Kotsaki E, Kaffe E, Karagianni N, **Koliaraki V**, Salpea K, Ragoussis J, Aidinis V, Martini E, Becker C, Hershman HR, Vetrano S, Danese S and Kollias G. Intestinal myofibroblast-specific Tpl2-Cox2-PGE2 pathway links innate sensing to epithelial homeostasis. *PNAS* 2014; 111(43): E4658-67.

*co-correspondence; **corresponding author

Pubmed link to the entire bibliography: [Pubmed-Koliaraki](#)